Sponsored by Sideways Frequency, LLC
Advancing the Future of Cancer Treatment with Next-Generation Therapies
Ropidoxuridine (IPdR) is a lead candidate radiation sensitizer designed for use in combination with radiation therapy (RT) to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure
Shuttle Pharmaceuticals has received Orphan Drug Designation from the FDA for IPdR, providing potential marketing exclusivity upon first FDA approval for the treatment of the disease
Read the Investor Presentation HERE
________________________
Hello Everyone,
Today’s profile shot up early on and exploded double digits before coming back down. We are certainly operating in volatile markets.
Let’s switch it up a bit today and give you tomorrow’s ticker ahead of time, while the after hours markets are still open.
Put SHPH on your screen right away and watch it immediately as we head into the last session of the week.
Founded in 2012 by faculty members of Georgetown University Medical Center, Shuttle Pharma is a discovery and development-stage specialty pharmaceutical company focused on enhancing outcomes for cancer patients undergoing radiation therapy (RT).
Dedicated to advancing therapies that maximize RT effectiveness while minimizing side effects, the company seeks to improve cancer treatment strategies. By developing radiation sensitizers, the goal is to increase cancer cure rates, extend patient survival, and enhance quality of life—whether used as a primary treatment or in combination with surgery, chemotherapy, and immunotherapy.
Shuttle Pharmaceuticals is dedicated to pioneering the next generation of radiation oncology treatments, aiming to transform cancer care. Achieving this goal requires innovation, expertise, and an unwavering commitment to scientific progress.
Through strategic collaborations and cutting-edge research, efforts are focused on pushing the boundaries of cancer treatment. By enhancing the effectiveness of radiation therapy, the mission is to improve patient outcomes, extend survival, and offer new hope to millions impacted by cancer worldwide.
Top Reasons to Have SHPH on Your Radar
Expanding Oncology Market: The global oncology market is projected to reach $903.81 billion by 2034,* presenting a massive growth opportunity for innovative cancer therapies.
Lead Candidate with Strong Potential: Ropidoxuridine (IPdR), a radiation sensitizer, seeks to enhance the effectiveness of radiation therapy for aggressive cancers like glioblastoma.
Orphan Drug Designation: IPdR has received FDA Orphan Drug Designation, which may provide market exclusivity upon approval, increasing its commercial potential.
- 04Pipeline of Therapeutic Candidates : In addition to Ropidoxuridine, three lead candidates are in development for the treatment of solid tumors, including breast cancer, lung cancer, and multiple myeloma.
- SP-2-225: A selective HDAC6 inhibitor, integral for antigen presentation by macrophages to T-lymphocytes.
- SP-1-303: A Class I HDAC inhibitor with preferential efficacy against ER-positive cancers.
- SP-1-161: A lead candidate that activates the ATM gene, which plays a critical role in DNA damage response and repair.
Growing Radiation Therapy Market: With 800,000 U.S. cancer patients receiving RT annually, and the global radiation therapy market expected to reach $12.93 billion by 2034,* demand for radiation sensitizers is increasing.
Diagnostics Expansion (PSMA-B Ligand, PC-Rad Test): SHPH is advancing next-generation diagnostics, including PSMA-B Ligand for prostate cancer imaging and PC-Rad Test, a novel diagnostic tool for precision radiation therapy.
Debt Level Advantage: SHPH has more cash than its total debt, strengthening its financial position and reducing risks for investors.
Strategic Partnerships & Collaborations: Partnering with Georgetown University Medical Center, UNC Medical Center, UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network Cancer Institute, and Miami Cancer Institute to advance clinical trials and research.
Positioned for Growth: The company appears well-positioned to capitalize on increasing demand for radiation sensitizers and advanced cancer treatments.
Potential First-Mover Advantage: As a company focused on improving radiation therapy outcomes, SHPH may secure an early lead in a growing and underserved market segment.
The Growing Cancer Burden and the Critical Need for Advanced Therapies
Cancer remains a major global challenge, with 20 million new cases and 9.7 million deaths recorded in 2022. One in five people develop cancer in their lifetime, and survival rates vary significantly. Prostate cancer, the second most diagnosed cancer among men, caused 396,000 deaths in 2022, with cases expected to rise to 2.4 million annually by 2040 *. This growing burden highlights the urgent need for improved treatments.
Rising Demand for Radiotherapy and Sensitizers
Radiotherapy is a key cancer treatment, with an estimated 10 million new patients needing it in 2022. By 2050, this number could rise to over 21 million . In the U.S., 800,000 cancer patients receive radiotherapy annually, half with curative intent. The demand for radiation sensitizers is expected to grow by over 22% in the next five years, creating a significant market for innovations that enhance treatment outcomes.
The Urgent Need for Better Glioblastoma Treatments
Glioblastoma (GBM), the most aggressive brain cancer, affects 3.19 per 100,000 people globally. Standard treatments—surgery, radiotherapy, and chemotherapy—face high recurrence rates, leading to poor patient outcomes. New approaches are essential to improve survival and quality of life.
Advancing Innovation in Cancer Care
With rising cancer cases and treatment limitations, the need for effective therapies is greater than ever. Radiation sensitizers present an opportunity to enhance radiotherapy’s impact, improve survival rates, and address treatment resistance, shaping the future of cancer care.
Therapeutics
Ropidoxuridine
Ropidoxuridine (IPdR) is our lead candidate radiation sensitizer for use in combination with radiation therapy (RT) to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.
We have received Orphan Drug Designation from the FDA for IPdR, providing potential marketing exclusivity upon first FDA approval for treatment of the disease.
Ropidoxuridine (IPdR) is an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and the cells become more sensitive to the effects of RT. The mechanisms underlying our candidate agents have been attributed to incorporation of IUdR, a metabolite of IPdR, into DNA, yielding reactive uracil free radicals that cause lethal DNA double strand breaks following radiation exposure.
HDAC Inhibitors
Shuttle Pharma’s HDAC inhibitors target cancer cell growth while sparing normal cells, regulating gene expression to restore tumor suppressor function. With over 20 patents, three lead candidates focus on treating solid tumors, including breast and lung cancer. These molecules enhance radiation sensitization, immune response activation, and precision oncology advancements.
Diagnostics
PSMA-B Ligand
PSMA-B Ligand is a novel boron-containing molecule designed for prostate cancer diagnosis and therapy. With strong PSMA binding, it aims to enhance proton radiation therapy and serves as a PET diagnostic and targeted treatment. Preclinical studies and a research partnership with UCSF aim to advance its development as a theranostic solution.
PC-Rad Test
The PC-Rad Test aims to address the unmet need for a predictive, minimally invasive blood test to assess prostate cancer patients’ responses to radiation therapy. Through licensed IP from Georgetown University, this biomarker program seeks to personalize treatment decisions, improve outcomes, and enhance patient-clinician decision-making in prostate cancer care.
Strategic Agreements
We have developed important strategic agreements and contractual relationships with academic institutions for access to resources such as intellectual property, core facilities and contracting relationships. Our relationships have included:
University of California, San Francisco (UCSF)
We entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of Shuttle Diagnostics, Inc.’s (a wholly-owned subsidiary of Shuttle Pharma) ligand to the prostate-specific membrane antigen (PSMA) as a potential diagnostic and therapeutic, or theranostic, molecule. UCSF researchers, led by principal investigator, Robert Flavell, M.D., PhD., will aim to develop radiosynthetic methods for producing [18F]FPA-ACUPA probe; investigate cellular binding properties of [18F]FPA-ACUPA in PCa cell lines; and investigate the diagnostic potential of the probe across various PCa phenotypes. Shuttle Pharma has an exclusive license to the PSMA-B intellectual property and has filed a patent application with the US Patent and Trademark Office.
Georgetown University
Georgetown University is an internationally recognized educational and research university engaged in the discovery and development of new cancer diagnostics and therapeutics through the programs of the Lombardi Comprehensive Cancer Center. Shuttle Pharmaceuticals subcontracted clinical aspects of SBIR funded research to establish cancer cell lines from African-American patients and to develop predictive biomarkers for patient sensitivity to radiation late-effects.
Brown University
We have received an SBIR contract from the NIH to fund a Phase I clinical trial in collaboration with Brown University at the Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in patients with advanced gastrointestinal cancers. In connection with the trial, NCI approved the Phase I clinical protocol and provided drug and clinical data management support to Rhode Island Hospital. The Phase I clinical trial has been completed and the results support advancing Ropidoxuridine to Phase II clinical trials of brain tumors, sarcomas and other tumors.
University of Virginia
The University of Virginia is an internationally recognized educational and research university engaged in the discovery and development of new cancer therapeutics and has developed the “Atomic Radiation” intellectual property. Shuttle Pharmaceuticals’ scientists collaborate with scientists at the University of Virginia to sensitizers for use with proton radiation therapy.
George Washington Cancer Center
Collaborations between the Villagra lab at George Washington University and the Shuttle Pharmaceuticals’ lab resulted in a joint presentation at the October 2020 AACR Conference of research addressing: “Immune-mediated Tumor Growth Inhibition by Selective HDAC6 Inhibitor SP-2-225.” Dr. Villagra has served as a Scientific Advisor to Shuttle Pharmaceuticals with expertise in cellular signaling pathways, epigenetics and immunology since 2017. We also have a material transfer agreement for testing HDAC inhibitor effects in immune model systems
TCG GreenChem
TCG GreenChem Inc. is a sister company of TCG Lifesciences Pvt. Ltd. Both are a part of the TCG Group based in New York, NY and together a leading global Custom Research and Manufacturing Services (CRAMS) company for drug discovery, development and commercialization. They have a presence in the United States, India, and Japan. TCG GreenChem Founder and Chief Executive Officer, Chris Senanayake, PhD along with Executive Vice President and Global Head of Research and Development, Executive Vice President and Global Head of Research and Development joined Shuttle’s leadership team in 2020 to manufacture drug product for use in proposed clinical trials.
NEWS
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
Mar 13, 2025
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
Mar 12, 2025
Mar 12, 2025
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
Feb 26, 2025
Jan 21, 2025
Jan 7, 2025
Dec 19, 2024
Nov 26, 2024
Oct 29, 2024
Shuttle Pharma Pays Off Senior Secured Convertible Note
Oct 29, 2024
Oct 29, 2024
Oct 28, 2024
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
Oct 28, 2024
Sep 16, 2024
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
Sep 11, 2024
Sep 5, 2024
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
Sep 4, 2024
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Aug 28, 2024
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
Aug 26, 2024
Aug 14, 2024
MANAGEMENT TEAM
Christopher Cooper
Interim CEO
Mr. Cooper has more than 27 years of experience in management and finance, having worked in the oil and gas, telecommunications and technology industries. In addition to his appointment as Interim Co-CEO of the Shuttle Pharma, Mr. Cooper also serves as President, CEO and Founder of First Towers & Fiber Corp., a telecommunications infrastructure company with operations in Latin America, positions he has held since 2017. From 2010 until 2017, Mr. Cooper served as President and CEO of Aroway Energy, Inc., a Vancouver, British Columbia-based oil and gas company, where he was responsible for overseeing day to day operations, financial reporting, and oversaw acquisitions and debt and equity financing. From 1998 until 2010, Mr. Cooper served as a Corporate Consultant to various companies in the technology and resources sectors, oversaw restricting activities for several distressed public companies, and was responsible for raising more than $100 million in debt and equity for his clients. Mr. Cooper received his MBA from Dowling College in 1995 and his BBA in Business Administration from Hofstra University.
Anatoly Dritschilo, MD
Chief Scientific Officer & Chairman
Dr. Dritschilo is a Company co-founder and has served as Chairman of the board of directors since December 2012. Dr. Dritschilo is an American Board of Radiology certified radiation oncologist with clinical experience treating cancer patients, directing basic science and clinical research projects and serving in administrative capacities as Department Chair at Georgetown University School of Medicine; Chief of Radiation Oncology at MedStar-Georgetown University Hospital; Medical Director of Georgetown University Hospital; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital and the MedStar Health Research Institute. His biotech experience includes co-founding Oncomed, Inc. and service as a member of the board of directors of Neopharm, Inc. His 250+ scientific publications and 20+ issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science (BS) degree in Chemical Engineering from the University of Pennsylvania, a Master’s Degree (MS) from the New Jersey Institute of Technology, a medical degree (MD) from the College of Medicine of New Jersey and completed residency training from the Harvard, Joint Center for Radiation Therapy.
Timothy Lorber, CPA
Chief Financial Officer
Mr. Lorber is a CPA with more than 40 years of professional finance experience, including 15 years with Legg Mason, Inc. (“Legg Mason”), one of the world’s larger public global asset management firms where he served as a Managing Director and Chief Accounting Officer until its sale in 2020. More recently, Mr. Lorber has served in leadership roles with several privately held businesses, overseeing finance, IT and HR functions. Prior to Legg Mason, Mr. Lorber served as Internal Audit Director of Freddie Mac and has also worked for several international public accounting firms.
Michael Vander Hoek, MHSA
Vice President, Regulatory
Mr. Vander Hoek serves as the Company’s Vice President, Regulatory. Previously he also served as the Company’s Chief Financial Officer, Prior to Mr. Tim Lorber joining the Company. Mr. Vander Hoek’s experience includes service as Director, Finance and Business Development at Georgetown Lombardi Comprehensive Cancer Center (“LCCC”), where he directed a five-year $221.9 million institutional commitment for cancer center research under an NCI-approved cancer consortium arrangement. His responsibilities included recruitment of scientists and senior leaders to address the Cancer Center’s mission. Previously, Mr. Vander Hoek served as Associate Director, Administration, at Georgetown’s LCCC, where he was directly responsible for t administrative operations and management of $216.9 million in institutional commitments to LCCC from Medstar Health, John Theurer Cancer Center (“JTCC”), and Georgetown University. Mr. Vander Hoek implemented an enterprise-wide clinical trial management system for Georgetown University and Medstar Health. Mr. Vander Hoek also served as the LCCC’s Chief Financial Officer negotiated research served as Vice-Chair, Planning and Administration, at MedStar Georgetown University Hospital. His financial management experience in publicly held companies includes Director of Managed Care Reimbursement for Critical Care America and Regional Controller for Laboratory Corporation of America (LabCorp) Mr. Vander Hoek holds a Master’s in Health Services Administration from George Washington University and a Bachelor of Arts in Biology and Psychology from Hope College.
Peter Dritschilo, MBA
President & COO
Mr. Dritschilo has served as our President and Chief Operating Officer since Shuttle Pharmaceuticals was formed in December 2012. He also served as our Chief Financial Officer until 2019. Mr. Dritschilo has more than 25 years of business management experience in medical services and cancer treatment. He has held administrative positions with Medstar-Rad America Georgetown University, Prince William Hospital/ Fauquier Hospital Cancer Center and Inova Health System’s Schar Cancer Institute. Mr. Dritschilo graduated from Georgetown University and received his MBA from George Washington University.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF EIGHT THOUSAND TWO HUNDRED FIFTY USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY SHPH AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.